ch128.1Av

ch128.1Av is a chimeric antibody-avidin fusion protein targeting the human transferrin receptor 1 (TfR1, also known as CD71). Developed by researchers at UCLA, this therapeutic candidate is designed for the treatment of multiple myeloma and other hematopoietic malignancies. The drug exerts its anti-tumor activity through a multifaceted mechanism: it binds to TfR1, inducing its internalization and subsequent degradation, which leads to lethal iron deprivation in malignant cells. Furthermore, ch128.1Av is capable of eliciting Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC). Preclinical studies in disseminated multiple myeloma xenograft mouse models have demonstrated significant anti-tumor activity and long-term survival, while assays on pluripotent hematopoietic progenitor cells suggest that the drug spares essential healthy progenitors.

Other names

anti-CD71 antibody-avidin fusion proteinanti-CD-71 antibody-avidin fusion proteinanti-CD 71 antibody-avidin fusion proteinch128.1-avidinch-128.1-avidinch 128.1-avidin